The OrthoAlloUnion consortium signed its project Grant Agreement on December 1, 2023, and received approval for a widening proposal involving the University of Aveiro (UAveiro#16) in January 2025. The Consortium Agreement was signed on February 12, 2024 (UAveiro#16 signed it retroactively from February 2, 2025). As for Periodic Report 2, two amendments to the grant agreement were conducted.
Overall, 36% of the actions were completed during this report, including the submission of 9 deliverables programmed for PR2, together with the 2 deliverables pending since PR1 (D2.5 and D4.3). Of the seven Milestones due since PR1, five have now been achieved. The remaining two (MS6: first batch release and MS7: first patient recruited) are still late, both linked to the additional quality control requirements, with patient recruitment now expected to begin in September 2026.
During this PR2, the consortium held 2 consortium meeting and 9 continuous meetings, focused on securing regulatory approvals for the clinical trial, coordinating production and clinical teams, and supporting the observational study, in addition to the Review Meeting scheduled after PR1.
The consortium made significant progress across scientific, cell production, and clinical objectives. Donor screening and Master Cell Bank manufacturing progressed successfully, enabling the manufacturing centres in France and Spain to be ready for production of the clinical doses, after selection of the best donors by UNIMORE#5.
On the clinical side, the trial was approved in France and Spain, with Italy and Germany under second evaluation, and the Spanish site ready to start recruitment in September 2026. The COHORTHOUnion cohort study is also progressing, with 237 of 502 cases included to date.
Further advances included the development of a multicellular 3D bone-like model integrating vascularisation, bone formation, and potential resorption under Task 4.3 pending confirmation of osteoclast resorptive activity through dedicated assays. Task 4.4. Progress on a ready-to-use packaging solution for the combined ATMP, with the design validated and suitability assessment ongoing. In Task 4.6 the development of placenta-derived cryogels with tunable protein concentrations shows a fully optimised Bone-on-Chip system, validated for microfluidic perfusion and confirmed system viability.